{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:03:58Z","timestamp":1761894238518},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2006,9,25]]},"DOI":"10.1007\/s10067-005-0181-2","type":"journal-article","created":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T20:01:54Z","timestamp":1138219314000},"page":"840-844","source":"Crossref","is-referenced-by-count":47,"title":["Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies"],"prefix":"10.1007","volume":"25","author":[{"given":"Wolfgang","family":"Miesbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Scharrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Asherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"181_CR1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309\u20131311","journal-title":"Arthritis Rheum"},{"key":"181_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-2776(08)60777-4","volume":"49","author":"HP McNeil","year":"1999","unstructured":"McNeil HP, Chesterman CN, Krilis SA (1999) Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193\u2013280","journal-title":"Adv Immunol"},{"key":"181_CR3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0741-5214(92)70024-F","volume":"15","author":"CK Shortell","year":"1992","unstructured":"Shortell CK, Ouriel K, Green RM, Condemi JJ, DeWeese JA (1992) Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis. J Vasc Surg 15:158\u2013165","journal-title":"J Vasc Surg"},{"key":"181_CR4","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","volume":"101","author":"M Galli","year":"2003","unstructured":"Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827\u20131832","journal-title":"Blood"},{"key":"181_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/jaut.2000.0404","volume":"15","author":"RA Asherson","year":"2000","unstructured":"Asherson RA (2000) Antiphospholipid antibodies, malignancies and paraproteinemias. J of Autoimmun 15:117\u2013122","journal-title":"J of Autoimmun"},{"key":"181_CR6","first-page":"195","volume":"154","author":"J-C Piette","year":"2000","unstructured":"Piette J-C, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y (2000) The catastrophic antiphospholipid syndrome\u2013Asherson\u2019s syndrome. Ann Med Interne 154:195\u2013196","journal-title":"Ann Med Interne"},{"key":"181_CR7","unstructured":"Trousseau A (1865) Phlegmasia alba dolens. In: Clinique Medical de L\u2019Hotel Dieu de Paris Vol 3 London. The New Sydenham Society, 1865:94"},{"key":"181_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-200111000-00002","volume":"80","author":"RA Asherson","year":"2001","unstructured":"Asherson RA, Cervera R, Piette JC et al (2001) Catastrophic antiphospholipid syndrome. Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:1\u201323","journal-title":"Medicine (Baltimore)"},{"key":"181_CR9","first-page":"2035","volume":"27","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Ito M, Nagata S, Suzuki H, Togawa A, Nagase M, Hishida A (2000) Catastrophical exacerbation of antiphospholipid syndrome after lung adenocarcinoma biopsy. J Rheumatol 27:2035\u20132037","journal-title":"J Rheumatol"},{"key":"181_CR10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1163\/156855900300109549","volume":"30","author":"P Soltesz","year":"2000","unstructured":"Soltesz P, Szekanecz Z, Vegh J, Lakos G, Toth L, Szakall S, Veres K, Szegedi G (2000) Catastrophic antiphospholipid syndrome in cancer. Haematologica 30:303\u2013311","journal-title":"Haematologica"},{"key":"181_CR11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1034\/j.1600-0609.2000.065005344.x","volume":"65","author":"I Genvresse","year":"2000","unstructured":"Genvresse I, Buttgereit F, Sp\u00e4th-Schwalbe E, Ziemer S, Eucker J, Possinger K (2000) Arterial thrombosis associated with anticardiolipin and anti-\u03b22-glycoprotein-I antibodies in patients with non-Hodgkin\u2019s lymphoma: a report of two cases. Eur J Haematol 65:344\u2013347","journal-title":"Eur J Haematol"},{"key":"181_CR12","first-page":"199","volume":"15","author":"S Faiderbe","year":"1991","unstructured":"Faiderbe S, Chagnaud JL, Charrier MC et al (1991) Antibodies directed against lipid membrane components in sera of patients with malignant tumours. Cancer Detec Prev 15:199\u2013203","journal-title":"Cancer Detec Prev"},{"key":"181_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9343(99)80355-6","volume":"98","author":"D Bessis","year":"1995","unstructured":"Bessis D, Sotto A, Viaid JP, Berard M, Civana AJ, Boffa M (1995) Trousseau\u2019s syndrome with non-bacterial thrombotic endocarditis: pathogenetic role of antiphospholipid syndrome. Am J Med 98:511\u2013513","journal-title":"Am J Med"},{"key":"181_CR14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMp030086","volume":"349","author":"RL Bick","year":"2003","unstructured":"Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109\u2013111","journal-title":"N Engl J Med"},{"key":"181_CR15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1055\/s-0038-1649901","volume":"74","author":"JT Brandt","year":"1995","unstructured":"Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185\u20131190","journal-title":"Thromb Haemost"},{"key":"181_CR16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/978-1-4471-3666-8_22","volume-title":"Hughes syndrome. Antiphospholipid syndrome","author":"IJ Mackie","year":"2000","unstructured":"Mackie IJ, Donohoe S, Machin SJ (2000) Lupus anticoagulant measurement. In: Khamashta MA (ed). Hughes syndrome. Antiphospholipid syndrome. Springer, Berlin Heidelberg New York, pp 214\u2013225"},{"key":"181_CR17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1055\/s-0038-1649701","volume":"70","author":"DA Triplett","year":"1993","unstructured":"Triplett DA, Stocker KF, Unger GA (1993) The Textarin\/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 70:925\u2013931","journal-title":"Thromb Haemost"},{"key":"181_CR18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V68.4.869.869","volume":"68","author":"P Thiagarajan","year":"1986","unstructured":"Thiagarajan P, Pengo V, Shapiro SS (1986) The use of the dilute Russel viper venome time for the diagnosis of lupus anticoagulants. Blood 68:869\u2013874","journal-title":"Blood"},{"key":"181_CR19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1191\/0961203302lu202cr","volume":"11","author":"EN Harris","year":"2002","unstructured":"Harris EN, Pierangeli SS (2002) Revisiting the anticardiolipin test and its standardization. Lupus 11:269\u2013275","journal-title":"Lupus"},{"key":"181_CR20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"181_CR21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-0038-1642734","volume":"73","author":"AL Campbell","year":"1995","unstructured":"Campbell AL, Pierangeli SS, Wellhausen S, Harris EN (1995) Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 73:529\u2013534","journal-title":"Thromb Haemost"},{"key":"181_CR22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/jaut.2000.0412","volume":"15","author":"PL Meroni","year":"2000","unstructured":"Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A (2000) Endothelial activation by aPL. A potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 15:237\u2013240","journal-title":"J Autoimmun"},{"key":"181_CR23","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/1529-0131(200111)44:11<2467::AID-ART426>3.0.CO;2-U","volume":"44","author":"PM Dobado-Berrios","year":"2001","unstructured":"Dobado-Berrios PM, Lopez-Pedreda C, Velazco F, Cuadrado MJ (2001) The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 44:2467\u20132476","journal-title":"Arthritis Rheum"},{"key":"181_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-995829","volume":"24","author":"JL Francis","year":"1998","unstructured":"Francis JL, Biggerstaff J, Amirkhosravi A (1998) Hemostasis and malignancy. Semin Thromb Hemost 24:93\u2013109","journal-title":"Semin Thromb Hemost"},{"key":"181_CR25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1995.353","volume":"72","author":"E Zuckerman","year":"1995","unstructured":"Zuckerman E, Toubi E, Golan T et al (1995) Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer 72:447\u2013451","journal-title":"Br J Cancer"},{"key":"181_CR26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0961203303lu328oa","volume":"12","author":"KH Yoon","year":"2003","unstructured":"Yoon KH, Wong A, Shakespeare T, Sivalingham P (2003) High prevalence of the antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 12:112\u2013116","journal-title":"Lupus"},{"key":"181_CR27","first-page":"175","volume":"24","author":"JF Schved","year":"1994","unstructured":"Schved JF, Dupuy-Fons C, Biron C et al (1994) A prospective epidemiological study of the occurrence of antiphospholipid antibody; the Montpelier Antiphospholipid (MAP) Study. Haemostasis 24:175\u2013182","journal-title":"Haemostasis"},{"key":"181_CR28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2257.1988.tb01152.x","volume":"10","author":"B Jude","year":"1988","unstructured":"Jude B, Goudermand J, Dolle I et al (1988) Lupus anticoagulant: a clinical study of 100 cases. Clin Lab Haematol 10:41\u201351","journal-title":"Clin Lab Haematol"},{"key":"181_CR29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0038-1649628","volume":"70","author":"R Stasi","year":"1993","unstructured":"Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Zaccari G, Papa G (1993) Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin\u2019s lymphoma. Thromb Haemost 70:568\u2013572","journal-title":"Thromb Haemost"},{"key":"181_CR30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<139::AID-AJH8>3.0.CO;2-X","volume":"57","author":"IS Lossos","year":"1998","unstructured":"Lossos IS, Bogomolski-Yahalom V, Hatzner Y (1998) Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Haematol 57:139\u2013143","journal-title":"Am J Haematol"},{"key":"181_CR31","first-page":"254","volume":"15","author":"K Lechner","year":"1985","unstructured":"Lechner K, Pabinger-Fasching I (1985) Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 15:254\u2013262","journal-title":"Haemostasis"},{"key":"181_CR32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","volume":"117","author":"MH Rosove","year":"1992","unstructured":"Rosove MH, Brewer PM (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic events in 70 patients. Ann Intern Med 117:303\u2013308","journal-title":"Ann Intern Med"},{"key":"181_CR33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90108-2","volume":"96","author":"JL Vianna","year":"1994","unstructured":"Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicentric study of 114 patients. Am J Med 96:3\u20139","journal-title":"Am J Med"},{"key":"181_CR34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0248-8663(01)00348-4","volume":"22","author":"E Liozon","year":"2001","unstructured":"Liozon E, Loustaud V, Jauberteau MO, Jaccard A, Soria P, Bordessoule D, Julia A, Vidal E (2001) Non-simultaneous malignant lymphoma and antiphospholipid syndrome: 4 cases. Rev Med Interne 22:360\u2013370","journal-title":"Rev Med Interne"},{"key":"181_CR35","first-page":"57","volume":"86","author":"A Sciarra","year":"1995","unstructured":"Sciarra A, Staai R, Stipa B et al (1995) Antifosfolipid prevalenza, significato clinico e correlazione con I livell di citochine nella leucemia mieloice e mel linfomanon-Hodgkin. Recentl Prog Med 86:57\u201362","journal-title":"Recentl Prog Med"},{"key":"181_CR36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1600-0609.2002.01526.x","volume":"68","author":"I Genvresse","year":"2002","unstructured":"Genvresse I, L\u00fcftner D, Sp\u00e4th-Schwalbe E, Buttgereit F (2002) Prevelance and clinical significance of anticardiolipin and anti-\u03b22-glycoprotein-I antibodies in patients with non-Hodgkin\u2019s lymphoma. Eur J Haematol 68:84\u201390","journal-title":"Eur J Haematol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0181-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-005-0181-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0181-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T10:14:29Z","timestamp":1586686469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-005-0181-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,25]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,9,25]]}},"alternative-id":["181"],"URL":"https:\/\/doi.org\/10.1007\/s10067-005-0181-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,25]]}}}